Pfizer wins the copayment lawsuit!

CompilationFan Dongdong

Last summer, Pfizer was accused of helping patients participating in the medical insurance program pay for the expensive cardiac drugs Vyndaqel and Vyndamax by means of subsidies from patient charities, resulting in the payment of nearly $24 million in the federal settlement.

Recently, the company filed an appeal in the Federal Court of New York to challenge the existing copayment and rebate policies in the United States

Pfizer calls for open donations and direct subsidies

In June last year, Pfizer sued HHS to help patients pay for the medical insurance copayments of two expensive new drugs

Pfizer is striving for the success of two appeals

In this regard, Michael said in a recent interview that although there have been "guidance methods" for independent charities to participate in co-payments, it is not clear whether the court will make a clear ruling on the plan

Infringe on freedom of speech, or induce consumption?

Pfizer believes that the HHS Office of Inspectorate (OIG) only restricts drugmakers and does not perform the same control on exchanges and donations in other industries, which violates the protection of freedom of speech provided by the First Amendment

In recent years, this practice has been frequently scrutinized by the US federal government, and has triggered a series of settlement agreements with major pharmaceutical companies for suspected violations of rebates

Assistant U.

Defense attorney Jacob Lillywhite believes that Pfizer’s litigation has directly challenged the courts, an unprecedented attempt to "subvert decades of established laws" and HHS's official opinions, with the purpose of "inducing" medical insurance beneficiaries to purchase the most expensive medical insurance in the history of the United States.

Allow co-payment, or it will upend drug prices in the U.

The US government generally does not negotiate drug costs, so "cost-sharing obligations virtually the only means of checking the price"

But Pfizer’s lawyer pointed out that Vyndaqel is used to treat transthyretin amyloid cardiomyopathy, which mainly affects elderly patients who are already eligible for medical insurance

The government's defense attorney Lillywhite raised an objection

Reference source: Pfizer victory in Vyndaqel copay lawsuit could kneecap the government's only control on prices, lawyer warns